Trial Profile
A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results discussing MRD analysis by ClonoSeq assay predicts outcomes in a prospective cohort of patients with advanced stage FL, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 06 Sep 2023 Planned End Date changed from 1 Jun 2023 to 1 Mar 2024.
- 04 Dec 2018 Results assessing sensitive assay for TP53 mutations applied to SWOG S0016 study, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.